Effexor (Venlafaxine) Voluntary Recall

ISSUE: Pfizer Inc. issued a voluntary recall of one lot of 30-count Effexor XR (venlafaxine HCl) 150 mg extended-release capsules, one lot of 90-count Effexor XR (venlafaxine HCl) 150 mg extended-release capsules, and one lot of 90-count Greenstone LLC-branded Venlafaxine HC1 150 mg extended-release capsules. This action is being taken because of a pharmacist report that one bottle of Pfizer’s Effexor XR contained one capsule of Tikosyn (dofetilide) 0.25mg in addition to the Effexor XR capsules.

The use of Tikosyn by an Effexor XR/Venlafaxine HCl patient, where the contraindications and drug-drug interactions with Tikosyn have not been considered by the prescribing physician, could cause serious adverse health consequences that could be fatal.

via Safety Alerts for Human Medical Products > Effexor XR 150 Mg Extended-Release Capsules (Pfizer) and Venlafaxine HCl 150 Mg Extended-Release Capsules (Greenstone): Recall – Possible Presence of Tikosyn Capsules.

Pharmacists are on alert but if you are taking one of these prescriptions check the pill before you take it.

Teens Likely to Get Opioid Rx for Headaches

The study, which was published in the Journal of Adolescent Healthanalyzed medical claims and pharmacy data from 8,373, 13- to 17-year-olds who visited a clinician for headache, which is a common ailment in adolescents.

Forty-six percent received one prescription for an opioid; 23% got two prescriptions and 29% got three or more prescriptions.

via Teens Likely to Get Opioid Rx for Headaches.

Killing Pain: Script by Script

Primary care doctors wrote about 53 million benzodiazepine prescriptions in 2013, roughly four times the number written by psychiatrists, a group that penned 13 million benzo scripts.

Nurse practitioners and physician assistants were close behind with 11 million prescriptions for the drugs, according to data obtained by MedPage Today and the Milwaukee Journal Sentinel.

In 2013, non-doctors wrote 30 million opioid prescriptions, compared with 92 million written by primary care doctors that year, according to data provided by IMS Health, a drug market research firm.

In 2010, the most recent year for which data were available, 30% of the 16,651 people who died of an opioid overdose also had taken a benzodiazepine, according to the U.S. Centers for Disease Control and Prevention.

via Killing Pain: Script by Script.

Killing Pain: Benzo ‘Boost’ Can Be Deadly.

Killing Pain: Xanax Tops Charts.

Testosterone Treatment and MI Risk

Filling a prescription for testosterone therapy was associated with a greater risk of having a nonfatal myocardial infarction (MI) in the next 3 months, a large observational study showed.

The risk after a prescription was filled was more than doubled in men 65 and older overall compared with that in the year before the prescription (rate ratio 2.19, 95% CI 1.27-3.77), according to Robert Hoover, MD, ScD, of the National Cancer Institute in Bethesda, Md., and colleagues.

The study was limited, however, by the observational design, the use of administrative data that lacked information on indications for treatment, and the inclusion of nonfatal MIs only.

via Study Feeds Concerns About MI Risk With Testosterone Tx.

Acetaminophen Prescription Combination Drug Products with more than 325 mg: FDA Statement – Recommendation to Discontinue Prescribing and Dispensing

ISSUE: FDA is recommending health care professionals discontinue prescribing and dispensing prescription combination drug products that contain more than 325 milligrams (mg) of acetaminophen per tablet, capsule or other dosage unit. There are no available data to show that taking more than 325 mg of acetaminophen per dosage unit provides additional benefit that outweighs the added risks for liver injury. Further, limiting the amount of acetaminophen per dosage unit will reduce the risk of severe liver injury from inadvertent acetaminophen overdose, which can lead to liver failure, liver transplant, and death.

via Safety Alerts for Human Medical Products > Acetaminophen Prescription Combination Drug Products with more than 325 mg: FDA Statement – Recommendation to Discontinue Prescribing and Dispensing.

You like your liver?  You can keep your liver.

Farxiga (dapagliflozin) – Think Diabetes

The FDA has approved dapagliflozin (Farxiga) for treatment of type 2 diabetes in adults, along with diet and exercise, the agency said in a statement.

The approval comes with strings, however: drugmakers Bristol-Myers Squibb and AstraZeneca must conduct six post-market studies, which include a cardiovascular outcomes trial in patients with baseline cardiovascular disease risks, a bladder cancer risk trial, an animal study looking at drug-induced urinary flow and bladder tumor promotion, two trials on risks in pediatric patients, and an enhanced pharmacovigilance program to study liver abnormalities and pregnancy outcomes.

via FDA Approves New Diabetes Drug.